Expanding the molecular grading criteria in IDH-mutant astrocytoma - PubMed
2 days ago
- #astrocytoma
- #molecular grading
- #prognostic markers
- IDH-mutant astrocytomas are classified as WHO grade 4 with high-grade histology or homozygous CDKN2A/B deletion per current guidelines.
- Study evaluated additional molecular alterations (CDK4, CCND2, PDGFRA, PIK3R1, MYCN, EGFR) in two cohorts (n=840 and n=367).
- These alterations were associated with reduced overall survival compared to grade 2/3 astrocytomas without them.
- 17.7% of grade 2/3 astrocytomas had one or more of these criteria, showing intermediate survival (67.3-82.0 months).
- Findings suggest adding these molecular markers to future classifications to improve risk stratification.